tmq it got beaten up too much on the YPF renationalisation because some dimwitted fundy doesn't know how to assess risk. I reckon she'll slowly/quickly get back to $2 in the short term where the cobra will meet resistance.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress